Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Alliqua Biomedical (ALQA) Stock Price

News coverage about Alliqua Biomedical (NASDAQ:ALQA) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alliqua Biomedical earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned news stories about the company an impact score of 43.9730192977196 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Separately, ValuEngine upgraded shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, March 1st.

Shares of Alliqua Biomedical stock remained flat at $$2.02 on Thursday. 84 shares of the stock traded hands, compared to its average volume of 63,901. Alliqua Biomedical has a fifty-two week low of $1.58 and a fifty-two week high of $4.60. The stock has a market cap of $10.01 million, a PE ratio of -0.31 and a beta of 0.94.

About Alliqua Biomedical

Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.

Insider Buying and Selling by Quarter for Alliqua Biomedical (NASDAQ:ALQA)

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply